Regulation of inflammatory responses in tumor necrosis factor–activated and rheumatoid arthritis synovial macrophages by JAK inhibitors
Open Access
- 31 August 2012
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (12) , 3856-3866
Abstract
Objective: JAK inhibitors have been developed as antiinflammatory and immunosuppressive agents and are currently undergoing testing in clinical trials. The JAK inhibitors CP‐690,550 (tofacitinib) and INCB018424 (ruxolitinib) have demonstrated clinical efficacy in rheumatoid arthritis (RA). However, the mechanisms that mediate the beneficial actions of these compounds are not known. The purpose of this study was to examine the effects of both JAK inhibitors on inflammatory and tumor necrosis factor (TNF) responses in human macrophages.Methods: In vitro studies were performed using peripheral blood macrophages derived from healthy donors and treated with TNF and using synovial fluid macrophages derived from patients with RA. Levels of activated STAT proteins and other transcription factors were detected by Western blotting, and gene expression was measured by real‐time polymerase chain reaction analysis. The in vivo effects of JAK inhibitors were evaluated in the K/BxN serum–transfer model of arthritis.Results: JAK inhibitors suppressed the activation and expression of STAT‐1 and downstream inflammatory target genes in TNF‐stimulated and RA synovial macrophages. In addition, JAK inhibitors decreased nuclear localization of NF‐κB subunits in TNF‐stimulated and RA synovial macrophages. CP‐690,550 significantly decreased the expression of interleukin‐6 in synovial macrophages. JAK inhibitors augmented nuclear levels of NF‐ATc1 and cJun, followed by increased formation of osteoclast‐like cells. CP‐690,550 strongly suppressed K/BxN serum–transfer arthritis, which is dependent on macrophages, but not lymphocytes.Conclusion: Our findings demonstrate that JAK inhibitors suppress macrophage activation and attenuate TNF responses and further suggest that suppression of cytokine/chemokine production and innate immunity contribute to the therapeutic efficacy of JAK inhibitors.Keywords
This publication has 49 references indexed in Scilit:
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondNature Reviews Drug Discovery, 2011
- The dynamics of macrophage lineage populations in inflammatory and autoimmune diseasesArthritis & Rheumatism, 2009
- Integration of cytokine and heterologous receptor signaling pathwaysNature Immunology, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)Journal of Medicinal Chemistry, 2008
- Suppression of the Effector Phase of Inflammatory Arthritis by Double-Stranded RNA Is Mediated by Type I IFNsThe Journal of Immunology, 2007
- Dysregulation of interleukin‐10–dependent gene expression in rheumatoid arthritis synovial macrophagesArthritis & Rheumatism, 2006
- Transcriptional regulation by calcium, calcineurin, and NFATGenes & Development, 2003
- Development of anti-TNF therapy for rheumatoid arthritisNature Reviews Immunology, 2002
- Anti-Cytokine Therapy for Rheumatoid ArthritisAnnual Review of Medicine, 2000